BioSpace News Archive

Auris Medical Holding Ltd. announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20.

Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

The company disclosed the data breach in a filing with the U.S. Securities and Exchange Commission on Tuesday. The hacking occurred in March and the company said the data of about 1 percent of its total number of clients was compromised.

Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.

The six projects focus on important topics surrounding adult congenital heart disease.

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2019 financial results after the market close on Tuesday, May 7, 2019.

IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., will participate in a panel discussion entitled, “IO Session I: Combination Failures & Futures: Much Ado About What?” at the 30th Annual Cancer Progress Conference in New York City on May 7-8, 2019.

Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington’s disease, ALS, prion disease and others

Triumvira Immunologics Inc. has simultaneously submitted an IND to the U.S. Food and Drug Administration and a CTA to Health Canada to initiate a Phase 1/2, first-in-human trial of TAC01-CD19, a TAC-T cell therapy product engineered to target CD-19 in patients with Relapsed/Refractory Large B-Cell Lymphoma.

Acceleron Pharma Inc. announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results.